PebRx has built a leadership and management team for execution across translational science, regulatory strategy, drug discovery, and market access, aligned around a single goal: getting the BRI-Series and its companion PET tracers to patients.
CEO
Experienced CEO of translational startups, Scientist, and Investment Banker. Life Science Entrepreneur with expertise in Venture Creation, IP Strategy, Fundraising and Partnership, and Drug Discovery and Preclinical Development.
Co-Founder & Scientific Lead
Bridges APOE4 biology with translational strategy across PebRx's therapeutic and diagnostic programs.
Co-Founder, Drug Development
Directs clinical development strategy for PebRx's lead programs.
Co-Founder, Drug Discovery
Leads small-molecule design and computational discovery for the cPLA2 inhibitor platform.
Pre-IND Project Manager
Directs pre-IND planning and project management across PebRx's therapeutic and diagnostic programs.
Backup Compound & PET Tracer Development
Advances next-generation cPLA2 compounds and PET tracer development.
Operations & Business Development
Drives operational execution and business development across PebRx's growing pipeline.
